Clinical and molecular features in patients with atypical teratoid rhabdoid tumor or malignant rhabdoid tumor.
Standard
Clinical and molecular features in patients with atypical teratoid rhabdoid tumor or malignant rhabdoid tumor. / Kordes, Uwe; Gesk, Stefan; Frühwald, Michael Christoph; Graf, Norbert; Leuschner, Ivo; Hasselblatt, Martin; Jeibmann, Astrid; Oyen, Florian; Peters, Ove; Pietsch, Torsten; Siebert, Reiner; Schneppenheim, Reinhard.
In: GENE CHROMOSOME CANC, Vol. 49, No. 2, 2, 2010, p. 176-181.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Clinical and molecular features in patients with atypical teratoid rhabdoid tumor or malignant rhabdoid tumor.
AU - Kordes, Uwe
AU - Gesk, Stefan
AU - Frühwald, Michael Christoph
AU - Graf, Norbert
AU - Leuschner, Ivo
AU - Hasselblatt, Martin
AU - Jeibmann, Astrid
AU - Oyen, Florian
AU - Peters, Ove
AU - Pietsch, Torsten
AU - Siebert, Reiner
AU - Schneppenheim, Reinhard
PY - 2010
Y1 - 2010
N2 - The SMARCB1 gene status in 50 patients with atypical teratoid rhabdoid tumor and/or malignant rhabdoid tumor recruited to a German registry was prospectively analyzed with FISH and PCR. Altogether we found 40 SMARCB1 mutations in 28 patients. Two patients were positive for SMARCB1 staining at immunochemistry. Germline mutations were identified in 10 of 41 patients with CNS disease, including three large heterozygous deletions, six truncating mutations and one donor splice site mutation. No missense mutation was identified. Analysis of first degree relatives did not detect any carriers. Mutations were distributed over the SMARCB1-gene without particular clustering. No germline mutation was found in nine patients without CNS disease. Patients with germline mutation had a lower median age at diagnosis in comparison to those without detectable germline mutation (5.5 vs. 13 months, P = 0.001), a higher rate of primary multicentric CNS disease (5/10 vs. 5/36) and synchronous or metachronous mixed CNS and extracranial disease (4/10 vs. 1/36). Two year overall survival was 0% in patients with germline mutation and 48% in those without detectable germline mutation (P <0.001). Patients with germline mutation of SMARCB1 manifest at an early age and have a very high risk for progression which has to be considered with respect to the outcome of further treatment studies.
AB - The SMARCB1 gene status in 50 patients with atypical teratoid rhabdoid tumor and/or malignant rhabdoid tumor recruited to a German registry was prospectively analyzed with FISH and PCR. Altogether we found 40 SMARCB1 mutations in 28 patients. Two patients were positive for SMARCB1 staining at immunochemistry. Germline mutations were identified in 10 of 41 patients with CNS disease, including three large heterozygous deletions, six truncating mutations and one donor splice site mutation. No missense mutation was identified. Analysis of first degree relatives did not detect any carriers. Mutations were distributed over the SMARCB1-gene without particular clustering. No germline mutation was found in nine patients without CNS disease. Patients with germline mutation had a lower median age at diagnosis in comparison to those without detectable germline mutation (5.5 vs. 13 months, P = 0.001), a higher rate of primary multicentric CNS disease (5/10 vs. 5/36) and synchronous or metachronous mixed CNS and extracranial disease (4/10 vs. 1/36). Two year overall survival was 0% in patients with germline mutation and 48% in those without detectable germline mutation (P <0.001). Patients with germline mutation of SMARCB1 manifest at an early age and have a very high risk for progression which has to be considered with respect to the outcome of further treatment studies.
M3 - SCORING: Zeitschriftenaufsatz
VL - 49
SP - 176
EP - 181
JO - GENE CHROMOSOME CANC
JF - GENE CHROMOSOME CANC
SN - 1045-2257
IS - 2
M1 - 2
ER -
